OGN

NEUTRALM&A

Organon & Co.

2026-07-31

Price

$13.55

+0.00%

This is the 2026-07-31 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score10.5Top Tier

Signals5/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume1.0xvs 20d avg

Analysis

OGN's price action is entirely dictated by its pending $14.00 per share all-cash acquisition by Sun Pharmaceutical, anchoring the stock in a tight holding pattern. The technical signals—ALPHA_MALE and QUIET_STORM—alongside a microscopic 3.2% realized volatility, perfectly reflect this merger arbitrage setup rather than organic price discovery. Despite mixed Q2 earnings reported on July 31, the stock remains flat as the broader RISK_ON macro regime and exceptionally tight credit spreads (0.80%) provide institutional confidence that the deal will close without financing or systemic hiccups.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACK

Key Takeaways

Actionable Thesis: OGN is a pure merger arbitrage play anchored to the $14/share Sun Pharma acquisition, offering a predictable but capped upside.
Key Risk: Regulatory pushback or unexpected antitrust roadblocks that could threaten the deal's expected early 2027 close.
What to Watch: Regulatory filings and deal timeline updates, as standalone fundamental earnings are now largely irrelevant to price action.

← Back to 2026-07-31 View Full OGN History →Yahoo Finance &nearr;